Hookipa Pharma Inc

HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its product includes VaxWace and TheraT. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, Katherine Cohen, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The firm also focuses on immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system. The company was founded by Rolf M. Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel D. Pinschewer in 2011 and is headquartered in New York, NY.

NEW YORK and VIENNA, Sept. 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that Katia Schlienger, M.D., Ph.D., is stepping down from her position as Chief Medical Officer (CMO) to pursue new opportunities, effective September 30. Malte Peters, M.D., a current member of the Board of Directors of HOOKIPA, will lead HOOKIPA's clinical activities ad interim as Senior Clinical Advisor until a CMO search is complete. During this time, Dr. Peters will remain a member of the HOOKIPA Board of Directors.

HOOKIPA Announces Executive Leadership Change

NEW YORK and VIENNA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-statutory options to new employees to purchase an aggregate of 100,000 shares of the Company's Common Stock under HOOKIPA's 2023 Inducement Plan. The award was granted as an inducement material to the employees's acceptance of employment with HOOKIPA in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $ 1.00 per share. The options have a ten year term and vest over four years, with 25% vesting on the one-year anniversary of the grant date and the remainder vesting in equal quarterly installments for three years thereafter, subject to the employee's continued service with HOOKIPA on each such vesting date. The options are subject to the terms and conditions of HOOKIPA's 2023 Inducement Plan approved by the Board of Directors in April 2023 and the terms and conditions of award agreements covering the grants.

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Invivyd Inc

Moderna

Novavax

Seelos Therapeutics

Zomedica

Amyris Inc

Investing in biotech stocks is not for the meek. Losses can be very large and occur very quickly.

7 Biotech Stocks to Sell in September Before They Crash & Burn

NEW YORK and VIENNA, Austria, Sept. 06, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA's management team will participate in and present at the following upcoming investor conferences:

HOOKIPA Pharma to participate in upcoming investor conferences in September

HOOKIPA Pharma Inc. (HOOK) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.23 per share a year ago.

HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Lags Revenue Estimates

NEW YORK and VIENNA, Austria, Aug. 10, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the second quarter of 2023.

HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

NEW YORK and VIENNA, Austria, Aug. 03, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its second quarter 2023 financial results and business highlights on August 10, 2023.

HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023

NEW YORK and VIENNA, Austria, June 10, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-statutory options to new employees to purchase an aggregate of 80,000 shares of the Company's Common Stock under HOOKIPA's 2023 Inducement Plan. The award was granted as an inducement material to the employees's acceptance of employment with HOOKIPA in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $ 1.01 per share. The options have a ten year term and vest over four years, with 25% vesting on the one-year anniversary of the grant date and the remainder vesting in equal quarterly installments for three years thereafter, subject to the employee's continued service with HOOKIPA on each such vesting date. The options are subject to the terms and conditions of HOOKIPA's 2023 Inducement Plan approved by the Board of Directors in April 2023 and the terms and conditions of award agreements covering the grants.

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and VIENNA, Austria, May 31, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the pricing of an underwritten public offering of 22,900,768 shares of its common stock and 15,268 shares of its non-voting Series A-2 convertible preferred stock (the “Offering”). The public offering price of each share of common stock is $1.31 and the public offering price of each share of non-voting Series A-2 preferred stock is $1,310.00 (each share of non-voting Series A-2 preferred stock is convertible into 1,000 shares of common stock). The gross proceeds to HOOKIPA from this offering are expected to be approximately $50.0 million, before deducting underwriting discounts and commissions and other offering expenses. All of the securities in the Offering are to be sold by HOOKIPA. The Offering is expected to close on June 5, 2023, subject to customary closing conditions.

HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock

eFFECTOR Therapeutics Inc

Taboola

This week has seen the stock market flip-flop, including the volatile world of penny stocks. Investors, especially those interested in high-risk, high-reward low-priced stocks, are attentively tracking the developments in Washington.

Stock Market Today: New Penny Stocks Trends & 3 To Watch This Week

NEW YORK and VIENNA, Austria, May 31, 2023 (GLOBE NEWSWIRE) --  HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive preliminary data from its ongoing Phase 2 study of HB-200 in combination with pembrolizumab in patients with recurrent/metastatic Human Papillomavirus 16-positive (HPV16+) head and neck cancer. New data show a 43 percent objective response rate (ORR) with HB-200 in combination with pembrolizumab in checkpoint inhibitor (CPI)-naïve patients, doubling the 19 percent response rate for pembrolizumab alone. HOOKIPA plans to share the full data at a medical conference later this year and is preparing to start a pivotal trial of HB-200 in combination with pembrolizumab in the 1st-line setting in 2024. The company will host a webcast call June 1st at 8:00 a.m. EDT.

HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers

HOOKIPA Pharma Inc. (HOOK) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.40 per share a year ago.

HOOKIPA Pharma Inc. (HOOK) Reports Q1 Loss, Lags Revenue Estimates

NEW YORK and VIENNA, May 11, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the first quarter of 2023.

HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

NEW YORK and VIENNA, Austria, May 09, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the first person has been dosed in a Gilead-led Phase 1 clinical trial of HB-400, an investigational therapeutic vaccine for chronic hepatitis B. HB-400 is one of two novel compounds being developed in collaboration with Gilead.

HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B

NEW YORK and VIENNA, Austria, May 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA's management team will participate in and present at the following upcoming investor conferences:

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May

NEW YORK and VIENNA, Austria, May 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its first quarter 2023 financial results and business highlights on May 11, 2023.

HOOKIPA Pharma to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 11, 2023

NEW YORK and VIENNA, Austria, April 26, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that a Trial in Progress poster on its ongoing Phase 1/2 clinical study (NCT05553639) of HB-300 in prostate cancer has been accepted for presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023.

HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO

NEW YORK and VIENNA, Austria, April 19, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today that the company will participate in investor meetings at the Van Lanschot Kempen Life Sciences Conference being held in Amsterdam, April 25 - 26, 2023.

HOOKIPA Pharma to Participate in the Van Lanschot Kempen Life Sciences Conference

Hookipa Pharma: A Speculative Biotech Worthy Of A Spot On My Watch List

HOOKIPA Pharma Inc. (NASDAQ:HOOK ) Q4 2022 Results Conference Call March 15, 2023 8:30 AM ET Company Participants Matthew Beck - Executive Director, Investor Relations Joern Aldag - Chief Executive Officer Reinhard Kandera - Chief Financial Officer Katia Schlienger - Chief Medical Officer Conference Call Participants Alec Stranahan - Bank of America Arthur He - H. C. Wainwright Asthika Goonewardene - Truist Securities Roy Buchanan - JMP Securities Suzanne van Voorthuizen - Kempen Operator Good morning and thank you for joining the HOOKIPA Pharma Fourth Quarter and Full Year 2022 Earnings and 2022 Outlook Conference Call.

HOOKIPA Pharma Inc. (HOOK) Q4 2022 Earnings Call Transcript

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 5.56% and 41.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates

NEW YORK and VIENNA, March 15, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and provided a corporate update for the fourth quarter and full year 2022, as well as the outlook for 2023.

HOOKIPA Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook

NEW YORK and VIENNA, March 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today that Terry Coelho will join its Board of Directors, Audit Committee and Compensation Committee, effective April 3, 2023.

HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors

NEW YORK and VIENNA, March 08, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release fourth quarter and full year 2022 financial results before the market opens on Wednesday, March 15, 2023. The Company will host a live conference call and webcast at 8:30 AM ET to discuss its financial results and provide a corporate update.

HOOKIPA Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 15, 2023

NEW YORK and VIENNA, Austria, Feb. 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced that it has achieved a $10 million non-dilutive milestone payment under its collaboration agreement with Roche to develop HB-700, a novel arenaviral immunotherapy for KRAS-mutated cancers. The success-based milestone payment reflects the start of the HB-700 manufacturing process to support a Phase 1 clinical trial. HOOKIPA plans to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration in the first half of 2024.

News for Hookipa Pharma Inc Stock (HOOK)